0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical and ultrasonic risk factors for high‐volume central lymph node metastasis in cN0 papillary thyroid microcarcinoma: A retrospective study and meta‐analysis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          Papillary thyroid microcarcinoma (PTMC) comprises more than 50% of all newly detected cases of papillary thyroid carcinoma (PTC). High‐volume lymph node metastasis (involving >5 lymph nodes) (hv‐LNM) is associated with PTMC recurrence. In half of the clinically node‐negative (cN0) PTMC patients, central lymph node metastasis (CLNM) is pathologically present. However, clinical risk factors for high‐volume CLNM (hv‐CLNM) in cN0 PTMC have not been defined well. Therefore, we aimed to obtain evidence for hv‐CLNM risk factors in cN0 PTMC.

          Design

          Data on patients who visited our hospital between January 2020 and December 2021 were collected; a preoperative diagnosis of cN0 and a postoperative pathological confirmation of PTMC were obtained. After filtering by inclusion versus exclusion criteria, the obtained data ( N = 2268) were included in the meta‐analysis. Relevant studies published as of 10 April 2022, were identified from the Web of Science, PubMed, WANFANG, and CNKI databases. These eligible studies were included in the meta‐analysis and the association between clinicopathological factors and hv‐CLNM in cN0 PTMC was assessed. SPSS and MetaXL were used for statistical analyses.

          Results

          The meta‐analysis included 10 previous studies (11,734 patients) and 2268 patients enroled in our hospital for a total of 14,002 subjects. The results of which suggested that younger age (<40, odds ratio [OR] = 3.28, 95% confidence interval [CI] = 2.75–3.92, p < .001 or <45 odds ratio [OR] = 2.93, 95% CI = 2.31–3.72, p < .001), male sex (OR = 2.81, 95% CI = 2.25–3.52, p < .001), tumour size >5 mm (OR = 1.85, 95% CI = 1.39–2.47, p < .001), multifocality (OR = 1.88, 95% CI = 1.56–2.26, p < .001), extrathyroidal extension (OR = 2.58, 95% CI = 2.02–3.30, p < .001), capsule invasion (OR = 2.02, 95% CI = 1.46–2.78, p < .001), microcalcification (OR = 3.25, 95% CI = 2.42–4.36, p < .001) and rich blood flow (OR = 1.65, 95% CI = 1.21–2.25, p = .002) were the significant factors related to an elevated hv‐CLNM risk in cN0 PTMC patients. Hashimoto thyroiditis (OR = 0.76, 95% CI = 0.55–1.07, p = .114), irregular margin (versus regular margin, OR = 0.96, 95% CI = 0.68–1.33, p = .787) and hypoechoic (versus nonhypoechoic, OR = 1.27, 95% CI = 0.84–1.92, p = .261) showed no significant association with hv‐CLNM.

          Conclusions

          Younger age, tumour size >5 mm, males, extrathyroidal extension, multifocality, microcalcification, capsular invasion, and rich blood flow were the significant clinicopathological risk factors for hv‐CLNM risk in cN0 PTMC patients. These predictors may compensate for the sensitivity of imaging diagnosis in the preoperative period, thus helping in the effective identification of PTMCs with an invasive phenotype.

          Related collections

          Most cited references76

          • Record: found
          • Abstract: found
          • Article: not found

          Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

          David Moher and colleagues introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

            Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Thyroid cancer

              Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clinical Endocrinology
                Clinical Endocrinology
                Wiley
                0300-0664
                1365-2265
                April 2023
                November 03 2022
                April 2023
                : 98
                : 4
                : 609-621
                Affiliations
                [1 ] Department of Thyroid Surgery The First Hospital of China Medical University Shenyang P. R. China
                Article
                10.1111/cen.14834
                36263602
                9a2235f9-13f7-4993-bc8b-88525d3f4e96
                © 2023

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article